64Cu-based Radiopharmaceuticals in Molecular Imaging.

64Cu-based Radiopharmaceuticals in Molecular Imaging. Technol Cancer Res Treat. 2019 Jan 01;18:1533033819830758 Authors: Zhou Y, Li J, Xu X, Zhao M, Zhang B, Deng S, Wu Y Abstract Copper-64 (T1/2 = 12.7 hours; β+: 19%, β-: 38%) has a unique decay profile and can be used for positron emission tomography imaging and radionuclide therapy. The well-established coordination chemistry of copper allows for its reaction with different types of chelator systems. It can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. Two potential ways to produce copper-64 radioisotopes concern the use of the cyclotron or the reactor. This review summarized several commonly used biomarkers of copper-64 radionuclide. PMID: 30764737 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30764737?dopt=Abstract

Source: Technology in Cancer Research and Treatment - January 1, 2019 Category: Cancer & Oncology Authors: Zhou Y, Li J, Xu X, Zhao M, Zhang B, Deng S, Wu Y Tags: Technol Cancer Res Treat Source Type: research